Selective Cancer Therapy by Extracellular Activation of a Highly Potent Glycosidic Duocarmycin Analogue
- 26 March 2013
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 10 (5) , 1773-1782
Abstract
Conventional cancer chemotherapy is limited by systemic toxicity and poor selectivity. Tumor-selective activation of glucuronide prodrugs by beta-glucuronidase in the tumor microenvironment in a monotherapeutic approach is one promising way to increase cancer selectivity. Here we examined the cellular requirement for enzymatic activation as well as the in vivo toxicity and antitumor activity of a glucuronide prodrug of a potent duocarmycin analogue that is active at low picomolar concentrations. Prodrug activation by intracellular and extracellular beta-glucuronidase was investigated by measuring prodrug 2 cytotoxicity against human cancer cell lines that displayed different endogenous levels of beta-glucuronidase, as well as against beta-glucuronidase-deficient fibroblasts and newly established beta-glucuronidase knockdown cancer lines. In all cases, glucuronide prodrug 2 was 1000–5000 times less cytotoxic than the parent duocarmycin analogue regardless of intracellular levels of beta-glucuronidase. By contrast, cancer cells that displayed tethered beta-glucuronidase on their plasma membrane were 80-fold more sensitive to glucuronide prodrug 2, demonstrating that prodrug activation depended primarily on extracellular rather than intracellular beta-glucuronidase activity. Glucuronide prodrug 2 (2.5 mg/kg) displayed greater antitumor activity and less systemic toxicity in vivo than the clinically used drug carboplatin (50 mg/kg) to mice bearing human lung cancer xenografts. Intratumoral injection of an adenoviral vector expressing membrane-tethered beta-glucuronidase dramatically enhanced the in vivo antitumor activity of prodrug 2. Our data provide evidence that increasing extracellular beta-glucuronidase activity in the tumor microenvironment can boost the therapeutic index of a highly potent glucuronide prodrug.Keywords
This publication has 50 references indexed in Scilit:
- Duocarmycin Analogues Target Aldehyde Dehydrogenase 1 in Lung Cancer CellsAngewandte Chemie International Edition, 2012
- Bacterial glucuronidase as general marker for oncolytic virotherapy or other biological therapiesJournal of Translational Medicine, 2011
- A Humanized Immunoenzyme with Enhanced Activity for Glucuronide Prodrug Activation in the Tumor MicroenvironmentBioconjugate Chemistry, 2011
- Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of β–glucuronidase in tumorsCancer Gene Therapy, 2011
- Glycosidic Prodrugs of Highly Potent Bifunctional Duocarmycin Derivatives for Selective Treatment of CancerAngewandte Chemie International Edition, 2010
- Investigation of the transformations of a novel anti-cancer agent combining HPLC, HPLC–MS and direct ESI–HRMS analysesAnalytical and Bioanalytical Chemistry, 2009
- Tumor-targeting prodrug-activating bacteria for cancer therapyCancer Gene Therapy, 2008
- Stable antibody expression at therapeutic levels using the 2A peptideNature Biotechnology, 2005
- Adenovirus-mediated interferon-β gene therapy suppresses growth and metastasis of human prostate cancer in nude miceCancer Gene Therapy, 2001
- Neighboring Carbon and Hydrogen. Li. Dienones from Ar1[UNK]-3 Participation. Isolation and Behavior of Spiro(2,5)octa-1,4-diene-3-oneJournal of the American Chemical Society, 1963